C92.0 Category · further specificity required Acute myeloblastic leukemia

ICD-10-CM C92.0 identifies “Acute myeloblastic leukemia” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.

Chapter 2: Neoplasms

Code-level instructions

Inclusion terms9
  • Acute myeloblastic leukemia, minimal differentiation
  • Acute myeloblastic leukemia (with maturation)
  • Acute myeloblastic leukemia 1/ETO
  • Acute myeloblastic leukemia M0
  • Acute myeloblastic leukemia M1
  • Acute myeloblastic leukemia M2
  • Acute myeloblastic leukemia with t(8;21)
  • Acute myeloblastic leukemia (without a FAB classification) NOS
  • Refractory anemia with excess blasts in transformation [RAEB T]
Excludes 12
  • acute exacerbation of chronic myeloid leukemia (C92.10)
  • refractory anemia with excess of blasts not in transformation (D46.2-)

Inherited instructions

Chapters 2 · Neoplasms (C00-D49)

Note8
  • Functional activity
  • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
  • Morphology [Histology]
  • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
  • Primary malignant neoplasms overlapping site boundaries
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
  • Malignant neoplasm of ectopic tissue
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).

C81-C96 · Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

Excludes 24
  • Kaposi's sarcoma of lymph nodes (C46.3)
  • secondary and unspecified neoplasm of lymph nodes (C77.-)
  • secondary neoplasm of bone marrow (C79.52)
  • secondary neoplasm of spleen (C78.89)

C92 · Myeloid leukemia

Includes2
  • granulocytic leukemia
  • myelogenous leukemia
Excludes 11

personal history of leukemia (Z85.6)

Code also1

, if applicable, pancytopenia (acquired) (D61.818)

More specific codes

Official index references

Official index references (5)

Leukemia, leukemic (4)
Myelosis (1)
References from other codes (2)
D64 · Other anemias

Excludes 1 · refractory anemia with excess blasts in transformation [RAEB T] (C92.0-)

History

Code history

Latest recorded change · FY2024

ChangedUnchanged
FY2024

Effective from

  • Inherited rules changed

Acute myeloblastic leukemia

Category — select a more specific code

CDC/NCHS · FY2024

All editions (19)

All editionsEffective fromCode history
FY20162015-10-01First observed
FY20172016-10-01No tabular change
FY20182017-10-01No tabular change
FY20192018-10-01No tabular change
FY20202019-10-01No tabular change
FY2020 · April2020-04-01No tabular change
FY20212020-10-01No tabular change
FY2021 · 01-012021-01-01No tabular change
FY20222021-10-01No tabular change
FY2022 · 04-012022-04-01No tabular change
FY20232022-10-01No tabular change
FY2023 · 04-012023-04-01No tabular change
FY20242023-10-01Inherited rules changed
FY2024 · 04-012024-04-01No tabular change
FY20252024-10-01No tabular change
FY2025 · 04-012025-04-01No tabular change
FY20262025-10-01No tabular change
FY2026 · April2026-04-01No tabular change
FY20272026-10-01No tabular change

Explore the more specific codes in this category. Reference checks do not establish clinical appropriateness or guarantee reimbursement.